Yoshiaki Nakayama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoshiaki Nakayama has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
Nobuyuki Itoh
Kyoto University Graduate School of Pharmaceutical Science, Kyoto, Japan
12 shared publicationsMorichika Konishi
Laboratory of Microbial Chemistry, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan
11 shared publicationsAyumi Miyake
Department of Genetic Biochemistry, Kyoto University Graduate School of Pharmaceutical Sciences
7 shared publicationsYuki Masuda
Laboratory of Microbial Chemistry Kobe Pharmaceutical University Kobe Japan
6 shared publications- Morichika Konishi
Laboratory of Microbial Chemistry, Kobe Pharmaceutical University, Kobe, Japan
5 shared publications Naosuke Nakamura
Laboratory of Neuroglycobiology, Department of Molecular Sciences, Faculty of Life Sciences, Kyoto Sangyo University, Kamigamo-motoyama, Kita-ku, Kyoto 603-8555, Japan
5 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 17 (18) , 8114-8126
Maitake mushroom supplementation modulates upper respiratory symptoms and immune responses in healthy adults: a randomized, double-blind, placebo-controlled trial
Maitake Y10M supplementation may reduce selected URTI-related symptom burden and modulate innate immune responses in healthy adults.
- 21 September 2026
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 17 (18) , 8114-8126
Open AccessMaitake mushroom supplementation modulates upper respiratory symptoms and immune responses in healthy adults: a randomized, double-blind, placebo-controlled trial
Maitake Y10M supplementation may reduce selected URTI-related symptom burden and modulate innate immune responses in healthy adults.
- Open Access
- 17 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (29) , eaee9999
FGF21 induced by endoplasmic reticulum stress maintains medullary thymic epithelial cell function and central immune tolerance
Medullary thymic epithelial cells (mTECs) establish central immune tolerance by expressing diverse tissue-restricted antigens and eliminating self-reactive thymocytes. Here, we show that fibroblast growth factor 21 (FGF21), although predominantly produced in the liver, is also expressed locally by mature mTECs and contributes to central tolerance. Fgf21 -deficient mice exhibited exacerbated peripheral autoimmune responses. FGF21 supported the number and function of mTECs and promoted clonal deletion in cooperation with thymic dendritic cells. In mature mTECs, endoplasmic reticulum stress induced FGF21 expression through unfolded protein response pathways, with FGF21 acting preferentially within the mature mTEC compartment as a stress-responsive metabolic regulator downstream of the integrated stress response. By limiting sustained stress and preserving protein homeostasis, FGF21 maintained mTEC integrity and central tolerance. These findings identify FGF21 as a key regulator of thymic immune homeostasis and as a potential therapeutic target for autoimmune disease.
- 17 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (29) , eaee9999
Open AccessFGF21 induced by endoplasmic reticulum stress maintains medullary thymic epithelial cell function and central immune tolerance
Medullary thymic epithelial cells (mTECs) establish central immune tolerance by expressing diverse tissue-restricted antigens and eliminating self-reactive thymocytes. Here, we show that fibroblast growth factor 21 (FGF21), although predominantly produced in the liver, is also expressed locally by mature mTECs and contributes to central tolerance. Fgf21 -deficient mice exhibited exacerbated peripheral autoimmune responses. FGF21 supported the number and function of mTECs and promoted clonal deletion in cooperation with thymic dendritic cells. In mature mTECs, endoplasmic reticulum stress induced FGF21 expression through unfolded protein response pathways, with FGF21 acting preferentially within the mature mTEC compartment as a stress-responsive metabolic regulator downstream of the integrated stress response. By limiting sustained stress and preserving protein homeostasis, FGF21 maintained mTEC integrity and central tolerance. These findings identify FGF21 as a key regulator of thymic immune homeostasis and as a potential therapeutic target for autoimmune disease.
- 25 April 2026
- Published by Wiley in The FEBS Journal
- Vol. 293 (20) , 6193-6207
Neudesin modulates IGF1 and insulin signaling pathways by regulating the surface expression of IGF1R through a conserved WPE motif
Neudesin, a secreted protein implicated in diverse physiological processes, such as metabolism and immunity, lacks an identified receptor, which has prevented a detailed understanding of its molecular mechanisms. In this study, we aimed to elucidate the function of neudesin by identifying its cognate receptor and investigating its effects on cellular signaling. Using a combination of phage display, bioinformatics, and biochemical analysis, we identified insulin‐like growth factor 1 receptor (IGF1R) as a high‐affinity receptor for neudesin, with a binding affinity of 1.78 ± 1.87 n m . This interaction was mediated by a conserved tryptophan‐proline‐glutamic acid (WPE) motif in the IGF1R extracellular domain. Our cellular assays revealed that, while neudesin binding to IGF1R induces basal phosphorylation of the downstream signaling molecules extracellular signal‐regulated kinase (ERK) and AKT (also known as Protein Kinase B, or PKB) in a cell‐line‐specific manner, it consistently acts as a negative modulator, attenuating both IGF1‐ and insulin‐induced signaling. Mechanistically, neudesin promoted the downregulation of cell surface IGF1R, thereby reducing the receptor pool available for ligand stimulation. Furthermore, neudesin inhibited insulin signaling, likely through the co‐internalization of IGF1R/insulin receptor (INSR) hybrid complexes. The physiological significance of this role was underscored in 3 T3‐L1 adipocytes, where neudesin knockdown enhanced insulin‐induced signaling and accelerated triglyceride accumulation. These results establish a novel molecular link between neudesin and the IGF1/insulin signaling axis, suggesting that neudesin may serve as an endogenous modulator of IGF1R/insulin activity, with potential implications for metabolic and growth‐related diseases.
- 25 April 2026
- Published by Wiley in The FEBS Journal
- Vol. 293 (20) , 6193-6207
Neudesin modulates IGF1 and insulin signaling pathways by regulating the surface expression of IGF1R through a conserved WPE motif
Neudesin, a secreted protein implicated in diverse physiological processes, such as metabolism and immunity, lacks an identified receptor, which has prevented a detailed understanding of its molecular mechanisms. In this study, we aimed to elucidate the function of neudesin by identifying its cognate receptor and investigating its effects on cellular signaling. Using a combination of phage display, bioinformatics, and biochemical analysis, we identified insulin‐like growth factor 1 receptor (IGF1R) as a high‐affinity receptor for neudesin, with a binding affinity of 1.78 ± 1.87 n m . This interaction was mediated by a conserved tryptophan‐proline‐glutamic acid (WPE) motif in the IGF1R extracellular domain. Our cellular assays revealed that, while neudesin binding to IGF1R induces basal phosphorylation of the downstream signaling molecules extracellular signal‐regulated kinase (ERK) and AKT (also known as Protein Kinase B, or PKB) in a cell‐line‐specific manner, it consistently acts as a negative modulator, attenuating both IGF1‐ and insulin‐induced signaling. Mechanistically, neudesin promoted the downregulation of cell surface IGF1R, thereby reducing the receptor pool available for ligand stimulation. Furthermore, neudesin inhibited insulin signaling, likely through the co‐internalization of IGF1R/insulin receptor (INSR) hybrid complexes. The physiological significance of this role was underscored in 3 T3‐L1 adipocytes, where neudesin knockdown enhanced insulin‐induced signaling and accelerated triglyceride accumulation. These results establish a novel molecular link between neudesin and the IGF1/insulin signaling axis, suggesting that neudesin may serve as an endogenous modulator of IGF1R/insulin activity, with potential implications for metabolic and growth‐related diseases.
- 13 September 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 784, 152647
Neudesin attenuates ischemic brain injury by regulating Nos2 expression in microglia
- 13 September 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 784, 152647
Neudesin attenuates ischemic brain injury by regulating Nos2 expression in microglia
- Open Access
- 25 January 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-11
A secretory protein neudesin regulates splenic red pulp macrophages in erythrophagocytosis and iron recycling
Neudesin, originally identified as a neurotrophic factor, has primarily been studied for its neural functions despite its widespread expression. Using 8-week-old neudesin knockout mice, we elucidated the role of neudesin in the spleen. The absence of neudesin caused mild splenomegaly, shortened lifespan of circulating erythrocytes, and abnormal recovery from phenylhydrazine-induced acute anemia. Blood cross-transfusion and splenectomy experiments revealed that the shortened lifespan of erythrocytes was attributable to splenic impairment. Further analysis revealed increased erythrophagocytosis and decreased iron stores in the splenic red pulp, which was linked to the upregulation of Fcγ receptors and iron-recycling genes in neudesin-deficient macrophages. In vitro analysis confirmed that neudesin suppressed erythrophagocytosis and expression of Fcγ receptors through ERK1/2 activation in heme-stimulated macrophages. Finally, we observed that 24-week-old neudesin knockout mice exhibited severe symptoms of anemia. Collectively, our results suggest that neudesin regulates the function of red pulp macrophages and contributes to erythrocyte and iron homeostasis.
- 25 January 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-11
Open AccessA secretory protein neudesin regulates splenic red pulp macrophages in erythrophagocytosis and iron recycling
Neudesin, originally identified as a neurotrophic factor, has primarily been studied for its neural functions despite its widespread expression. Using 8-week-old neudesin knockout mice, we elucidated the role of neudesin in the spleen. The absence of neudesin caused mild splenomegaly, shortened lifespan of circulating erythrocytes, and abnormal recovery from phenylhydrazine-induced acute anemia. Blood cross-transfusion and splenectomy experiments revealed that the shortened lifespan of erythrocytes was attributable to splenic impairment. Further analysis revealed increased erythrophagocytosis and decreased iron stores in the splenic red pulp, which was linked to the upregulation of Fcγ receptors and iron-recycling genes in neudesin-deficient macrophages. In vitro analysis confirmed that neudesin suppressed erythrophagocytosis and expression of Fcγ receptors through ERK1/2 activation in heme-stimulated macrophages. Finally, we observed that 24-week-old neudesin knockout mice exhibited severe symptoms of anemia. Collectively, our results suggest that neudesin regulates the function of red pulp macrophages and contributes to erythrocyte and iron homeostasis.
- 1 February 2019
- Published by Elsevier in International Immunopharmacology
- Vol. 67, 408-416
Maturation of dendritic cells by maitake α-glucan enhances anti-cancer effect of dendritic cell vaccination
- 1 February 2019
- Published by Elsevier in International Immunopharmacology
- Vol. 67, 408-416
Maturation of dendritic cells by maitake α-glucan enhances anti-cancer effect of dendritic cell vaccination
- 1 July 2016
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 136 (7) , 1051-1064
Interdisciplinary Subject “Yakugaku Nyumon” for First-year Students Constructed with Lectures and Problem-based Learning
In 2013, Kobe Pharmaceutical University established "Yakugaku Nyumon", an interdisciplinary course, which consists of omnibus lectures and problem-based learning (PBL) on topics ranging from basic to clinical subjects. The themes of the PBL were original ones; "Study from package inserts of aspirin", which aimed to reinforce the contents of the interdisciplinary lectures, and "Let's think about aspirin derivatives (super-aspirin)", which aimed to engender an interest in studying pharmacy. The PBL featured questions from teachers to help with study and was therefore referred to as "question-led PBL" (Q-PBL). The Q-PBL regarding aspirin derivatives began with preparing answers to the questions for a small group discussion (SGD) as an assignment, followed by a SGD, a presentation, and peer-feedback. From an analysis of the questionnaire survey, it was found that students considered the Q-PBL satisfying and that they had achieved the 4 aims: (1) to increase the motivation to study, (2) to enhance an understanding of the relations and significance of basic and clinical sciences, (3) to comprehend the learning content, and (4) to recognize the importance of communication. The Q-PBL with assignments has two favorable points. One is that the first-year students can challenge difficult and high-level questions when they are given these as assignments. The other is that students, who are unfamiliar with SGD can engage in discussions with other students using the knowledge gained from the assignment. The introduction of omnibus lectures and Q-PBL, along with these improvements in theme, application, and review process, promises increased learning efficacy at the university.
- 1 July 2016
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 136 (7) , 1051-1064
Interdisciplinary Subject “Yakugaku Nyumon” for First-year Students Constructed with Lectures and Problem-based Learning
In 2013, Kobe Pharmaceutical University established "Yakugaku Nyumon", an interdisciplinary course, which consists of omnibus lectures and problem-based learning (PBL) on topics ranging from basic to clinical subjects. The themes of the PBL were original ones; "Study from package inserts of aspirin", which aimed to reinforce the contents of the interdisciplinary lectures, and "Let's think about aspirin derivatives (super-aspirin)", which aimed to engender an interest in studying pharmacy. The PBL featured questions from teachers to help with study and was therefore referred to as "question-led PBL" (Q-PBL). The Q-PBL regarding aspirin derivatives began with preparing answers to the questions for a small group discussion (SGD) as an assignment, followed by a SGD, a presentation, and peer-feedback. From an analysis of the questionnaire survey, it was found that students considered the Q-PBL satisfying and that they had achieved the 4 aims: (1) to increase the motivation to study, (2) to enhance an understanding of the relations and significance of basic and clinical sciences, (3) to comprehend the learning content, and (4) to recognize the importance of communication. The Q-PBL with assignments has two favorable points. One is that the first-year students can challenge difficult and high-level questions when they are given these as assignments. The other is that students, who are unfamiliar with SGD can engage in discussions with other students using the knowledge gained from the assignment. The introduction of omnibus lectures and Q-PBL, along with these improvements in theme, application, and review process, promises increased learning efficacy at the university.
- Open Access
- 13 April 2016
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 4, 30
Roles of FGFs As Paracrine or Endocrine Signals in Liver Development, Health, and Disease
The liver plays important roles in multiple processes including metabolism, the immune system, and detoxification and also has a unique capacity for regeneration. FGFs are growth factors that have diverse functions in development, health, and disease. The FGF family now comprises 22 members. Several FGFs have been shown to play roles as paracrine signals in liver development, health, and disease. FGF8 and FGF10 are involved in embryonic liver development, FGF7 and FGF9 in repair in response to liver injury, and FGF5, FGF8, FGF9, FGF17, and FGF18 in the development and progression of hepatocellular carcinoma. In contrast, FGF15/19 and FGF21 are endocrine signals. FGF15/19, which is produced in the ileum, is a negative regulator of bile acid metabolism and a stimulator of gallbladder filling. FGF15/19 is a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. It is also required for hepatocellular carcinoma and liver regeneration. FGF21 is a hepatokine produced in the liver. FGF21 regulates glucose and lipid metabolism in white adipose tissue. Serum FGF21 levels are elevated in non-alcoholic fatty liver. FGF21 also protects against non-alcoholic fatty liver. These findings provide new insights into roles of FGFs in the liver and potential therapeutic strategies for hepatic disorders.
- 13 April 2016
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 4, 30
Open AccessRoles of FGFs As Paracrine or Endocrine Signals in Liver Development, Health, and Disease
The liver plays important roles in multiple processes including metabolism, the immune system, and detoxification and also has a unique capacity for regeneration. FGFs are growth factors that have diverse functions in development, health, and disease. The FGF family now comprises 22 members. Several FGFs have been shown to play roles as paracrine signals in liver development, health, and disease. FGF8 and FGF10 are involved in embryonic liver development, FGF7 and FGF9 in repair in response to liver injury, and FGF5, FGF8, FGF9, FGF17, and FGF18 in the development and progression of hepatocellular carcinoma. In contrast, FGF15/19 and FGF21 are endocrine signals. FGF15/19, which is produced in the ileum, is a negative regulator of bile acid metabolism and a stimulator of gallbladder filling. FGF15/19 is a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. It is also required for hepatocellular carcinoma and liver regeneration. FGF21 is a hepatokine produced in the liver. FGF21 regulates glucose and lipid metabolism in white adipose tissue. Serum FGF21 levels are elevated in non-alcoholic fatty liver. FGF21 also protects against non-alcoholic fatty liver. These findings provide new insights into roles of FGFs in the liver and potential therapeutic strategies for hepatic disorders.
- 1 February 2016
- Vol. 88 (1) , 86-93
[Secreted factor, FGF21, regulates diverse biological processes].
- 1 February 2016
- Vol. 88 (1) , 86-93
[Secreted factor, FGF21, regulates diverse biological processes].
- 21 August 2015
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 98 (6) , 1015-1025
Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity
The maturation of dendritic cells into more-immunostimulatory dendritic cells by stimulation with different combinations of immunologic agents is expected to provide efficient, adoptive immunotherapy against cancer. Soluble β-glucan maitake D-fraction, extracted from the maitake mushroom Grifola frondosa, acts as a potent immunotherapeutic agent, eliciting innate and adoptive immune responses, thereby contributing to its antitumor activity. Here, we evaluated the efficacy of maitake D-fraction, in combination with a Toll-like receptor agonist, to treat tumors in a murine model. Our results showed that maitake D-fraction, in combination with the Toll-like receptor 9 agonist, cytosine–phosphate–guanine oligodeoxynucleotide, synergistically increased the expression of dendritic cell maturation markers and interleukin-12 production in dendritic cells, but it did not increase interleukin-10 production, generating strong effector dendritic cells with an augmented capacity for efficiently priming an antigen-specific, T helper 1–type T cell response. Maitake D-fraction enhances cytosine–phosphate–guanine oligodeoxynucleotide-induced dendritic cell maturation and cytokine responses in a dectin-1–dependent pathway. We further showed that a combination therapy using cytosine–phosphate–guanine oligodeoxynucleotide and maitake D-fraction was highly effective, either as adjuvants for dendritic cell vaccination or by direct administration against murine tumor. Therapeutic responses to direct administration were associated with increased CD11c+ dendritic cells in the tumor site and the induction of interferon-γ–producing CD4+ and CD8+ T cells. Our results indicate that maitake D-fraction and cytosine–phosphate–guanine oligodeoxynucleotide synergistically activated dendritic cells, resulting in tumor regression via an antitumor T helper cell 1–type response. Our findings provide the basis for a potent antitumor therapy using a novel combination of immunologic agents for future clinical immunotherapy studies in patients.
- 21 August 2015
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 98 (6) , 1015-1025
Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity
The maturation of dendritic cells into more-immunostimulatory dendritic cells by stimulation with different combinations of immunologic agents is expected to provide efficient, adoptive immunotherapy against cancer. Soluble β-glucan maitake D-fraction, extracted from the maitake mushroom Grifola frondosa, acts as a potent immunotherapeutic agent, eliciting innate and adoptive immune responses, thereby contributing to its antitumor activity. Here, we evaluated the efficacy of maitake D-fraction, in combination with a Toll-like receptor agonist, to treat tumors in a murine model. Our results showed that maitake D-fraction, in combination with the Toll-like receptor 9 agonist, cytosine–phosphate–guanine oligodeoxynucleotide, synergistically increased the expression of dendritic cell maturation markers and interleukin-12 production in dendritic cells, but it did not increase interleukin-10 production, generating strong effector dendritic cells with an augmented capacity for efficiently priming an antigen-specific, T helper 1–type T cell response. Maitake D-fraction enhances cytosine–phosphate–guanine oligodeoxynucleotide-induced dendritic cell maturation and cytokine responses in a dectin-1–dependent pathway. We further showed that a combination therapy using cytosine–phosphate–guanine oligodeoxynucleotide and maitake D-fraction was highly effective, either as adjuvants for dendritic cell vaccination or by direct administration against murine tumor. Therapeutic responses to direct administration were associated with increased CD11c+ dendritic cells in the tumor site and the induction of interferon-γ–producing CD4+ and CD8+ T cells. Our results indicate that maitake D-fraction and cytosine–phosphate–guanine oligodeoxynucleotide synergistically activated dendritic cells, resulting in tumor regression via an antitumor T helper cell 1–type response. Our findings provide the basis for a potent antitumor therapy using a novel combination of immunologic agents for future clinical immunotherapy studies in patients.